Filing Details
Aligos Therapeutics, Inc. (NASDAQ:ALGS) filed a Form 8-K with the Securities and Exchange Commission on November 06, 2026, disclosing a material event.
8k filedNASDAQ:ALGS
Aligos Therapeutics, Inc. (ALGS) Reports Material Event to SEC
Aligos Therapeutics, Inc. (NASDAQ:ALGS) filed a Form 8-K with the Securities and Exchange Commission on November 06, 2026, disclosing a material event.
At publication ·
What changed
Aligos Therapeutics, Inc. (NASDAQ:ALGS) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Aligos Therapeutics filed a Form 8-K on November 6, 2026, disclosing a material event that shareholders should know about.
- The company's stock trades at $4.51 with a market capitalization of $43.3 million.
- Form 8-K filings report material events such as leadership changes, agreements, acquisitions, or asset sales between regular reports.
Market Context
Aligos Therapeutics, Inc.'s stock currently trades at $4.51 with a market capitalization of $43.3M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Aligos Therapeutics, Inc.'s stock.
All SEC filings for Aligos Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ALGS Stock Page
Frequently Asked Questions
Where can I read ALGS's SEC filings?
Browse all filings on our ALGS SEC filings page.
What types of SEC filings does Aligos Therapeutics, Inc. file?
Public companies like Aligos Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.